Teva Pharmaceutical Industries ADR (TEVA) Stock Price, Quote & News

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 914 8213

Website: www.tevapharm.com

Address:

124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel

Terrordomo80 Jul. 19 at 6:06 PM

$TEVA Schmucktard Dopewiser took a picture of the one lonely moment TEVA hit 35.96 and still wishing he sold some there...its 32.08 🤡 and stuck in range...and you'd better hope they blowout #s come ER...otherwise you already know...

0 · Reply

clan Jul. 18 at 3:34 PM

$ELTP Elite is becoming more elite every day. 👀 $JNJ $TEVA 👀 🇺🇲💪

0 · Reply

clan Jul. 18 at 12:57 PM

$ELTP $SPY $TEVA Elite Pharma. Don't sleep on Elite. 🇺🇲💪 🐂

0 · Reply

clan Jul. 18 at 1:09 AM

$ELTP $TEVA $JNJ @LieutenantJoe Here comes another money-maker for Elite. 💲🐂

0 · Reply

Makingmillions192 Jul. 14 at 1:53 PM

$GPCR $ALT $TEVA While Big Pharma races to acquire oral GLP-1 delivery tech, this platform developer is about to drop human and next-gen animal datasets that could rewrite the market's tolerability standards. The Late-Summer Data Drop Schedule: Lexaria Bioscience: LEXX Mid-August 2026 | Animal Study #2 (GLP-1-A26-2) Pharma is watching platform compatibility and PK data for tomorrow's next-gen blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. Late August / Early September 2026 | Human Study #7 (GLP-1-H26-7) THE MAIN EVENT. Head-to-head 5-week steady-state human data comparing DehydraTECH-semaglutide tablets directly against Wegovy. Pharma is tracking bio-absorption and a projected ~40% reduction in GI side effects. Early September 2026 | Animal Study #1 (GLP-1-A26-1) Pharma is watching alternative novel formulations designed to bypass or improve upon traditional, erratic SNAC-inclusive carriers.

0 · Reply

topstockalerts Jul. 13 at 7:56 PM

A U.S. federal appeals court on Monday revived Teva Pharmaceuticals' lawsuit against Eli Lilly, ruling that Teva can pursue claims that Lilly breached a 2018 settlement agreement related to the launch of a generic version of osteoporosis drug Forteo. The Seventh Circuit reversed a lower court's dismissal, concluding that questions over when the settlement agreement expired cannot be resolved solely from the contract's language and must be examined further in court. The dispute began after Lilly sued Teva in 2016 over alleged patent infringement. The companies later reached a settlement allowing Teva to launch its generic product in 2019, shortly before the relevant patents expired. However, Lilly later received an additional three years of FDA exclusivity in 2020, delaying generic competition. Teva argues that the extended exclusivity improperly postponed its launch until December 2023. $TEVA $LLY

0 · Reply

RunnerSignals Jul. 10 at 7:30 PM

late reversal scan $TEVA $VZLA show real buying despite sub-60% volume, while $AA looks more like short covering. consensus is watching headlines. smart money is testing reversal levels

0 · Reply

Hopewisper Jul. 10 at 12:57 PM

$TEVA Alllllll good news and we are goging down🦧🌞😂🕺

0 · Reply

tkstockpicker Jul. 9 at 3:41 PM

$TEVA Trying again here for another trade

0 · Reply

G101SPM Jul. 9 at 12:53 PM

$TEVA $33.11 bid Holding long position at profit. BRIEF: Teva Pharma's International GmbH and Polpharma Biologics International AG announce a global licensing agreement. note: The agreement grants Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to Ocrevus (ocrelizumab), upon regulatory approval. Under the terms of the agreement, Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar candidate. Teva will be responsible for regulatory submissions and, upon approval, commercialization of the intravenous and subcutaneous formulations in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey.

0 · Reply

Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Thu, 09 Jul 2026 12:12:04 -0400 - 10 days ago

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

2026-07-09T12:56:21.000Z - 10 days ago

Teva, Polpharma enter global licensing agreement for Ocrevus biosimilar

Jul 9, 2026, 8:45 AM EDT - 10 days ago

Market Cap	36.83B
Revenue (ttm)	17.26B
Net Income (ttm)	1.41B
EPS (ttm)	N/A
PE Ratio	11.43
Forward PE	16.23
Profit Margin	8.18%
Debt to Equity Ratio	2.02

Volume	3,612,300
Avg Vol	5,855,730
Day's Range	N/A - N/A
Shares Out	1.15B
Stochastic %K	19%
Beta	0.86
Analysts	Strong Sell
Price Target	$38.73